Positions

Overview

  • After graduating from medical school at the University of Tsukuba in Japan, Dr Osuka completed a residency program in Neurosurgery. While he was involved in the treatment of many types of diseases during his residency training, he developed a great interest in malignant brain tumors. Caring for patients with malignant brain tumors gave him first-hand experience with the difficulties of disease control and severe outcome for the patients. These experiences prompted his interest in training in basic research to acquire the skills and knowledge to develop more effective therapies for brain tumors. In parallel with his clinical practice, he started to conduct basic research on brain tumors.
    To further improve his basic knowledge about brain tumor biology, he then entered graduate school and joined the laboratory of Dr. Hideyuki Saya at Keio University in Tokyo to train in neuro-oncology research. His dissertation work focused on discovering mechanisms of Glioma stem cell (GSC) resistance to fractionated irradiation. He established an experimental model to study the acquisition of radioresistance in GSCs following sequential in vitro radiotherapy, and revealed a critical role for the IGF1 signaling pathway.
    To further his research training in molecular neuro-oncology and gain experience in a different scientific environment, he subsequently joined Dr. Van Meir’s laboratory as a postdoctoral fellow, at the end of 2014. In his laboratory, he have expanded his experience and expertise in molecular biology and brain tumor biology. He conducted two main projects. The first project was to analyze the radioresistance mechanism of GSCs, which was an extension of his dissertation work. He developed additional radioresistance models, including 5 models of human GSCs and one more mouse GSC. By using these models, he found that GSCs can acquire radioresistance by increasing N-cadherin expression, which reduces pro-proliferative Wnt--catenin signaling and Clusterin expression, which is anti-apoptotic. These results are to be published in the Journal of Clinical Investigation (Osuka S. et al, 2021). The second project is to analyze the role of adhesion GPCR BAI1 in the malignancy of glioblastoma and medulloblastoma.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2021 Targeting HIF-activated collagen prolyl 4-hydroxylase expression disrupts collagen deposition and blocks primary and metastatic uveal melanoma growthOncogene.  40:5182-5191. 2021
    2021 N-cadherin upregulation mediates adaptive radioresistance in glioblastomaJournal of Clinical Investigation.  131. 2021
    2021 Progression-free survival of prostate cancer patients is prolonged with a higher regucalcin expression in the tumor tissues: Overexpressed regucalcin suppresses the growth and bone activity in human prostate cancer cellsTranslational Oncology.  14. 2021
    2020 A Chimeric Signal Peptide–Galectin-3 Conjugate Induces Glycosylation-Dependent Cancer Cell–Specific ApoptosisClinical Cancer Research.  26:2711-2724. 2020
    2019 Arylsulfonamide 64B inhibits hypoxia/ HIF-induced expression of c-Met and CXCR4 and reduces primary tumor growth and metastasis of uveal melanomaClinical Cancer Research.  25:2206-2218. 2019
    2019 Early-life microbiota exposure restricts myeloid-derived suppressor cell–driven colonic tumorigenesisCancer Immunology Research.  7:544-551. 2019
    2019 Prolonged survival of renal cancer patients is concomitant with a higher regucalcin gene expression in tumor tissues: Overexpression of regucalcin suppresses the growth of human renal cell carcinoma cells in vitroInternational Journal of Oncology.  54:188-198. 2019
    2018 Prolonged survival of patients with colorectal cancer is associated with a higher regucalcin gene expression: Overexpression of regucalcin suppresses the growth of human colorectal carcinoma cells in vitroInternational Journal of Oncology.  53:1313-1322. 2018
    2018 BAI1 Suppresses Medulloblastoma Formation by Protecting p53 from Mdm2-Mediated DegradationCancer Cell.  33:1004-1016.e5. 2018
    2017 IL-36γ signaling controls the induced regulatory T cell-Th9 cell balance via NFκB activation and STAT transcription factorsMucosal Immunology.  10:1455-1467. 2017
    2017 Cancer therapy: Neutrophils traffic in cancer nanodrugsNature Nanotechnology.  12:616-618. 2017
    2017 Intertumoral Heterogeneity within Medulloblastoma SubgroupsCancer Cell.  31:737-754.e6. 2017
    2017 Assessment of PD-1 positive cells on initial and secondary resected tumor specimens of newly diagnosed glioblastoma and its implications on patient outcomeJournal of Neuro-Oncology.  133:277-285. 2017
    2017 Survival of lung cancer patients is prolonged with higher regucalcin gene expression: suppressed proliferation of lung adenocarcinoma A549 cells in vitro 2017
    2017 Overcoming therapeutic resistance in glioblastoma: The way forwardJournal of Clinical Investigation.  127:415-426. 2017
    2016 Prolonged survival in hepatocarcinoma patients with increased regucalcin gene expression: HepG2 cell proliferation is suppressed by overexpression of regucalcin in vitroInternational Journal of Oncology.  49:1686-1694. 2016
    2016 Increased regucalcin gene expression extends survival in breast cancer patients: Overexpression of regucalcin suppresses the proliferation and metastatic bone activity in MDA-MB-231 human breast cancer cells in vitroInternational Journal of Oncology.  49:812-822. 2016
    2016 Therapeutic impact of cytoreductive surgery and irradiation of posterior fossa ependymoma in the molecular era: A retrospective multicohort analysisJournal of Clinical Oncology.  34:2468-2477. 2016
    2016 Prolonged survival in pancreatic cancer patients with increased regucalcin gene expression: Overexpression of regucalcin suppresses the proliferation in human pancreatic cancer MIA PaCa-2 cells in vitroInternational Journal of Oncology.  48:1955-1964. 2016
    2016 Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis 2016
    2014 IGF2 preserves osteosarcoma cell survival by creating an autophagic state of dormancy that protects cells against chemotherapeutic stressCancer Research.  74:6531-6541. 2014
    2014 CXCL12 secreted from glioma stem cells regulates their proliferationJournal of Neuro-Oncology.  117:43-51. 2014
    2014 Integrated analysis identifies different metabolic signatures for tumor-initiating cells in a murine glioblastoma modelNeuro-Oncology.  16:1048-1056. 2014
    2013 Clinical characteristics and neuroimaging findings in 12 cases of recurrent glioblastoma with communicating hydrocephalus 2013
    2013 The patient had a normal magnetic resonance imaging and temporal lobe epilepsy secondary to a porencephalic cyst but showed structural lesions (hippocampal sclerosis)Epilepsy and Behavior Case Reports.  1:153-156. 2013
    2013 IGF1 receptor signaling regulates adaptive radioprotection in glioma stem cellsSTEM CELLS.  31:627-640. 2013
    2013 Decrease in the apparent diffusion coefficient in peritumoral edema for the assessment of recurrent glioblastoma treated by bevacizumab. 2013
    2012 Elevated diffusion anisotropy in gray matter and the degree of brain compression: Clinical articleJournal of Neurosurgery.  117:363-371. 2012
    2012 Valproic acid inhibits angiogenesis in vitro and glioma angiogenesis in vivo in the brain 2012
    2011 Invasion precedes tumor mass formation in a malignant brain tumor model of genetically modified neural stem cellsNeoplasia.  13:784-791. 2011
    2010 Detection of failure of bevacizumab treatment for malignant glioma based on urinary matrix metalloproteinase activity 2010
    2010 Metronomic treatment of malignant glioma xenografts with irinotecan (CPT-11) inhibits angiogenesis and tumor growthJournal of Neuro-Oncology.  99:177-185. 2010
    2010 Evaluation of ventriculomegaly using diffusion tensor imaging: Correlations with chronic hydrocephalus and atrophyJournal of Neurosurgery.  112:832-839. 2010
    2010 Diffusion tensor imaging in patients with adult chronic idiopathic hydrocephalus.Neurosurgery.  67. 2010
    2010 Mild encephalitis/encephalopathy with a reversible splenial lesion: evaluation by diffusion tensor imaging. Two case reports. 2010
    2008 A case report of germinoma with synchronous lesions in the thalamus and para lateral ventricle 2008
    2007 Endoscopic observation of pathophysiology of ventricular diverticulumChild's Nervous System.  23:897-900. 2007
    2007 Long-term outcome of patients with intracranial germinomaJournal of Neuro-Oncology.  83:71-79. 2007
    2007 Neurocysticercosis as solitary parenchymal lesion confirmed by mitochondrial deoxyribonucleic acid sequence analysis - Case report 2007

    Research Overview

  • My interest focuses on understanding the cellular and molecular biology of therapeutic resistance in brain tumors and how I can utilize such knowledge to explore new molecular targeting therapy and improve patient survival. We examine what types of cellular and molecular biology systems are important for resistance in human brain tumors, and in a mouse model of brain tumors. The knowledge generated in my study has the potential to provide new therapeutic options for patients suffering from brain tumors in the future and improve overall survival.
  • Education And Training

  • Doctor of Philosophy in Medical Clinical Sciences / Graduate Medical Studies, University of Tsukuba 2013
  • Doctor of Medicine, University of Tsukuba 2003
  • Full Name

  • Satoru Osuka